Company Filing History:
Years Active: 2005
Title: Edmund Differding: Innovator in Asthma and Allergy Treatment
Introduction
Edmund Differding is a notable inventor based in Louvain-la-Neuve, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of asthma and allergic disorders. His innovative work has led to the development of compounds that address critical health issues.
Latest Patents
Edmund Differding holds a patent for "Compounds and methods for treatment of asthma, allergy and inflammatory disorders." This invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines. The compounds are designed to act as dual-acting molecules, possessing both leukotriene inhibition and antihistaminergic properties. These compounds are particularly useful for treating conditions that involve histamine and/or leukotriene components, including asthma, allergic rhinitis, and various inflammatory disorders.
Career Highlights
Differding's career is marked by his dedication to research and development in the pharmaceutical industry. He is currently associated with UCB S.A., a company known for its focus on innovative biopharmaceuticals. His work has contributed to advancements in treatments that improve the quality of life for individuals suffering from respiratory and allergic conditions.
Collaborations
Throughout his career, Edmund Differding has collaborated with esteemed colleagues, including Ralph Scannell and Pierre P Chatelain. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of effective therapeutic solutions.
Conclusion
Edmund Differding's contributions to the field of asthma and allergy treatment exemplify the impact of innovative thinking in healthcare. His patented compounds represent a significant advancement in the management of allergic and inflammatory disorders.